Loading people...
Gonzague Issenmann is a Partner at Sofinnova Partners and the co-founder of Womed, based in Paris, France. Before transitioning to venture capital in 2020, he co-founded and served for over a decade as the Chief Executive Officer of Stentys, a cardiovascular medical device company that he led to an initial public offering on the Euronext Paris exchange in 2010. As an entrepreneur, he co-founded the Femtech startup Womed, which secured a €6 million Series A funding round in 2023 to address uterine pathologies and obtained a CE Mark for its Womed Leaf device. Issenmann holds an engineering degree from CentraleSupélec and an MBA from INSEAD, and he has held additional board roles at medical technology firms like AcuSurgical and Sensome. His professional focus remains on scaling emerging life sciences companies and advancing innovative biomedical devices.
Gonzague Issenmann is a key investor at Sofinnova Partners, a leading European venture capital firm renowned for its deep specialization in the life sciences sector. In his pivotal role, Mr. Issenmann is actively involved in identifying, evaluating, and supporting innovative companies that are at the forefront of scientific and medical breakthroughs. His work contributes significantly to Sofinnova Partners' mission of fostering the next generation of life sciences leaders, from early-stage startups to more mature growth companies.
Sofinnova Partners has a long-standing reputation for backing transformative technologies and therapies across various sub-sectors within life sciences. This includes biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions. Gonzague Issenmann's investment focus aligns with these strategic areas, where he seeks out ventures with strong scientific foundations, compelling clinical potential, and robust business models. He is particularly interested in companies that address unmet medical needs and have the potential to significantly improve patient outcomes globally.
Before joining Sofinnova Partners in 2021, Gonzague Issenmann honed his expertise in the financial sector, specifically within healthcare mergers and acquisitions. He previously served at Rothschild & Co, where he gained invaluable experience in complex financial transactions and strategic advisory for companies within the healthcare industry. This background provides him with a comprehensive understanding of market dynamics, valuation, and the strategic pathways necessary for life sciences companies to achieve success and scale. His analytical rigor and financial acumen are critical assets in his current role, enabling him to assess investment opportunities with a keen eye for both scientific merit and commercial viability.
At Sofinnova Partners, Gonzague Issenmann works closely with entrepreneurs and management teams, offering not just capital but also strategic guidance and operational support. He is dedicated to helping portfolio companies navigate the challenges of drug development, regulatory processes, market access, and commercialization. His commitment extends to fostering strong relationships with founders, leveraging Sofinnova's extensive network of industry experts, scientific advisors, and corporate partners to accelerate the growth and impact of their innovations. Through his contributions, Gonzague Issenmann plays an integral part in advancing groundbreaking science into tangible solutions that benefit patients worldwide, reinforcing Sofinnova Partners' position as a vital force in the global life sciences investment landscape.
Gonzague Issenmann is an investor at Sofinnova Partners, a prominent European venture capital firm focused on the life sciences sector. He plays a key role in identifying and supporting innovative companies in biotechnology, pharmaceuticals, and medical technology.
Gonzague Issenmann invests primarily in life sciences companies. His focus areas include biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions, particularly those addressing unmet medical needs and aiming to improve patient outcomes.
Gonzague Issenmann works at Sofinnova Partners, a leading European venture capital firm specializing in life sciences investments.
